Key facts
- This page summarizes Howard Levy's Form 4 filing for CATALYST BIOSCIENCES, INC. (GYRE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Aug 2021, 09:14.
Howard Levy - 09 Aug 2021 Form 4 Insider Report for CATALYST BIOSCIENCES, INC. (GYRE)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- GYRE
- Reported as of
- 09 Aug 2021
- Net transaction value
- +$2,313
- Reporting owner signature
- /s/ Seline Miller, Attorney-in-Fact for Howard Levy
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Howard Levy filed Form 4 for CATALYST BIOSCIENCES, INC. (GYRE) on 11 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$2,313.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CBIO
transaction
Common Stock
Purchase
- Transaction value
- $2,313
- Shares
- +639
- Change %
- Price
- $3.62*
- Shares after
- 639
- Date
- 09 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
CBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 23,390
- Date
- 09 Aug 2021
- Ownership
- By Howard and Gillian Levy Revocable Trust dated November 21, 1994
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2021.